RAPP — Rapport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2012593 ·
Last close
$40.98
Market Cap
$1.96B
52W High
$44.28
52W Low
$32.84
ADV30
419,123
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,000,000 | — | -24,215,000 | -19,857,000 | 497,597,000 | 78,056,000 | 26,085,000 |
| Dec 2025 | 0 | — | -38,509,000 | -33,763,000 | 512,431,000 | 52,645,000 | 27,778,000 |
| Sep 2025 | 0 | — | -29,986,000 | -26,925,000 | 535,323,000 | 251,359,000 | 23,706,000 |
| Jun 2025 | 0 | — | -29,496,000 | -26,732,000 | 285,495,000 | 55,067,000 | 21,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,473,000
Investing CF
$-187,473,000
Financing CF
$270,786,000
CapEx
$-616,000
Dividends Paid
—
Buybacks
$-1,000
EPS Diluted TTM
$-2.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-235,228,000
Inventory
—
Receivables
—
ST Investments
$437,894,000
EBIT TTM
$-125,099,000
Pretax Income TTM
$-111,483,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-121,206,000
Free Cash Flow
$-49,431,752
Enterprise Value
$1,493,968,512
Total Cash
$476,782,016
Total Debt
$10,803,000
Shares Out
47,826,929
Trailing EPS
$-2.60
Book Value
$9.86
ROE
-28.3%
ROA
-19.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -125,099,000 | -111,483,000 | 512,431,000 | 27,778,000 | — | -87,473,000 |
| Dec 2024 | 0 | -83,055,000 | -78,307,000 | 314,933,000 | 9,506,000 | — | -64,828,000 |
| Dec 2023 | 0 | -36,179,000 | -34,786,000 | 155,423,000 | 181,057,000 | — | -27,181,000 |
| Dec 2022 | — | — | — | 31,603,000 | 41,665,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.27
Max Pain — expiry 2027-02-19
max pain strike: $40.00 · spot: $40.98 · call oi: 1,658 · put oi: 828Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | $1.97B | $10.01 | — |
| NBTX | Nanobiotix S.A. | $1.95B | $38.38 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.98B | $31.44 | — |
| HCM | HUTCHMED (China) Ltd | $1.93B | $11.13 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $139.04 | — |
News headlines (Yahoo Finance, 1h cache)
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
2026-07-12 23:53 · Yahoo
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
2026-06-16 15:08 · Yahoo
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
2026-06-08 02:08 · Yahoo
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
2026-06-05 21:03 · Yahoo
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-20 20:05 · Yahoo
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2026-05-07 12:50 · Yahoo
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-05-07 11:00 · Yahoo
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
2026-04-30 13:04 · Yahoo
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
2026-04-27 20:17 · Yahoo
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
2026-04-21 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.